²é¿´: 1054  |  »Ø¸´: 1
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

csu03712

ľ³æ (ÖøÃûдÊÖ)

[ÇóÖú] ÇóÖú·­ÒëÒ»¶ÎÓ¢ÎÄÎÄÏ×£¨¸ß·Ö×ӾۺϷ½Ïò£©

Ò²¿ÉÒÔ·­ÒëÆäÖÐÒ»¶Î£¬Ð»Ð»£¡
      Bacterial drug resistance has become a serious problem in hospitals and community environments, as currently used treatments with broad-spectrum antibiotics are becoming progressively less effective.1 One of the most dangerous
human pathogens in this regard is methicillin-resistant Staphylococcus aureus (MRSA), an opportunistic microbe commonly found in skin abrasions and open wounds.

       Without treatment, these drug-resistant infections can lead  rapidly to the onset of bacteremia, sepsis, and toxic shock  syndrome.2-4 Drug-resistant infections claim thousands of  lives annually in the United States, and antibiotic therapy has  been reduced to only a few approved therapies. This problem
will most certainly continue to escalate as antibiotic resistance becomes even more widespread and serious. In addition to issues relating to acquired antibiotic resistance, many antibiotics are generally less effective in treating infections in fatty tissue, biofilms, or along the surfaces of bone and artificial devices where drug-resistant bacterial infections are so often found.9 Some lipophilic antimicrobials
are also limited to topical application because of their low water solubility for systemic administration.

     Our laboratory has become interested in exploring the use of nanoparticle-based antibiotics as potential treatments for life-threatening bacterial infections. One obvious use of the nanoparticles would be for enhancing performance of
antibacterial drugs that otherwise suffers from poor water solubility, stability, toxicity, or pharmacokinetics and distribution. Many lipid, phospholipid, and triglyceride-based emulsions containing droplets at the submicron level have
shown benefits when used for drug delivery, including delivering the dissolved drug solely to its intended destination in the body, providing the drug with controlled release, increasing the uptake and efficiency of the drug, and also reducing the inherent toxicity of the drug monomer, as in the case of amphotericin B.11-18 More recently, nanoparticles made from metals, fullerenes, synthetic and natural polymers, and various lipids have been investigated for certain drug delivery applications,19-25 a process wrought with questions and concerns relating to their ultimate benefits, applications, and potential drawbacks. One of the major concerns with the use of nanomaterials is the heightened risk of toxicity due to their extremely small size, their physical properties, their unknown chemical and biochemical interactions, as well as their ease of penetration through cellular and blood-brain barriers. Toxicological analysis of metal-based nanoparticles
in solution has been underway for some time,20,22,24; however, evaluation of new nanoparticle materials for cytotoxic or systemic toxicity has not kept up with the rapid evolution of the nanotechnology field. Polyacrylates have been used since the 1960s as biomedical coatings on devices and surgical glues, and are considered nontoxic26-35; moreover, emulsified polyacrylates, likewise, have been
studied as colloidal drug carriers.11-18,28,36-41 However, data on toxicity and biocompatibility of polyacrylate nanoparticles  (having diameters b100 nm) is severely lacking.
»°ËµÎÒµÄÍ·ÏñºÜ»ÎÑÛ¡¤¡¤¡¤¡¤¡¤¡¤
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ʯ¾°ºê

½û³æ (ÕýʽдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

csu03712(½ð±Ò+5, ·­ÒëEPI+1): 2011-05-12 09:58:18
ÔÚÒ½ÔººÍÉçÇø»·¾³ÖÐϸ¾úµÄ¿¹Ò©ÐÔÒѾ­³ÉΪһ¸öÑÏÖØµÄÎÊÌ⣬Èçµ±ÏÂËùÓõĹâÆ×¿¹Ò©ÐÔ·½·¨Öð½¥Ê§È¥Ð§¹û£¬ÆäÖÐÔÚÕâ·½ÃæÌåÏÖÍ»³öµÄÊÇÒ»ÖÖ×îÀ÷º¦µÄÈËÀಡԭÌåÄͼ×ÑõÎ÷ÁÖ½ðÆÏ¾ú£¬ÔÚÆ¤·ô²ÁÉË´¦ºÍ¿ª·ÅÐÔÉ˿ڴ¦¾­³£·¢ÏÖÒ»ÖÖ»ú»áÐÔµÄ΢ÉúÎï¡£
½¡¿µ¿ìÀֵĻîמÍÊÇ×î´óµÄÐÒ¸££¡
2Â¥2011-05-11 12:05:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ csu03712 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[½Ìʦ֮¼Ò] ΪʲôÖйú´óѧ¹¤¿Æ½ÌÊÚÃÇË®ÁËÄÇô¶àËùνµÄ¶¥»á¶¥¿¯£¬µ«»¹ÊÇ×ö²»³öÓîÊ÷»úÆ÷ÈË£¿ +5 »¶ÀÖËÌÒ¶Ýè 2026-02-21 8/400 2026-02-23 09:19 by »¶ÀÖËÌÒ¶Ýè
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 w89i99eaeh 2026-02-22 5/250 2026-02-23 08:04 by w4l55oybr1
[²©ºóÖ®¼Ò] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 6/300 2026-02-23 07:59 by w4l55oybr1
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 khieu8v8m0 2026-02-22 7/350 2026-02-23 07:54 by w4l55oybr1
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 7/350 2026-02-23 07:51 by w4l55oybr1
[²©ºóÖ®¼Ò] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +6 3dfhjxgsh7 2026-02-22 9/450 2026-02-23 07:49 by w4l55oybr1
[¿¼²©] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 4/200 2026-02-23 06:46 by jsjzfl
[˶²©¼ÒÔ°] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 8rmuugja8q 2026-02-22 6/300 2026-02-23 06:39 by w4l55oybr1
[¹«Åɳö¹ú] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 khieu8v8m0 2026-02-22 5/250 2026-02-23 06:29 by w4l55oybr1
[˶²©¼ÒÔ°] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 8/400 2026-02-23 06:24 by w4l55oybr1
[¿¼²©] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +5 3dfhjxgsh7 2026-02-22 6/300 2026-02-23 02:04 by 5jlh3qtdvx
[½Ìʦ֮¼Ò] °æÃæ·Ñ¸Ã½»Âð +7 Æ»¹ûÔÚÄÄÀï 2026-02-22 8/400 2026-02-22 22:37 by otani
[»ù½ðÉêÇë] »ù½ðÕýÎÄ30Ò³Ö¸µÄÊDZ¨¸æÕýÎÄ»¹ÊÇÕû¸öÉêÇëÊé +5 successhe 2026-02-16 6/300 2026-02-22 21:38 by ɽÎ÷Ðü¿ÕË¿ÕÐüÎ
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 usprnugpzw 2026-02-21 6/300 2026-02-22 19:48 by w89i99eaeh
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 3dfhjxgsh7 2026-02-22 4/200 2026-02-22 16:52 by khieu8v8m0
[ÕÒ¹¤×÷] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 usprnugpzw 2026-02-22 3/150 2026-02-22 16:37 by khieu8v8m0
[¹«Åɳö¹ú] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 usprnugpzw 2026-02-21 4/200 2026-02-22 16:27 by khieu8v8m0
[»ù½ðÉêÇë] ¡°ÈËÎÄÉç¿Æ¶øÂÛ£¬Ðí¶àѧÊõÑо¿»¹Ã»ÓдﵽÃñ¹úʱÆÚµÄˮƽ¡± +4 ËÕ¶«ÆÂ¶þÊÀ 2026-02-18 5/250 2026-02-22 16:07 by liangep1573
[»ù½ðÉêÇë] ½ñÄê´ºÍíÓм¸¸ö½ÚÄ¿ºÜ²»´í£¬µãÔÞ£¡ +11 ˲ϢÓîÖæ 2026-02-16 12/600 2026-02-21 21:14 by lq493392203
[»ù½ðÉêÇë] ÌåÖÆÄÚ³¤±²ËµÌåÖÆÄÚ¾ø´ó²¿·ÖÒ»±²×ÓÔڵײ㣬ÈçͬÄãÃÇÒ»Ñù´ó²¿·ÖÆÕͨ½ÌʦæÇÒÊÕÈëµÍ +9 ˲ϢÓîÖæ 2026-02-20 12/600 2026-02-21 10:39 by »¶ÀÖËÌÒ¶Ýè
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û